http://www.twitter.comTwitter is a service for friends, family, and co-workers to communicate and stay connected through the exchange of quick, frequent answers to one simple question: What are you doing?
View Older Stories View More Recent Stories
-
Anavex Life Sciences to Announce Fiscal 2025 Second Quarter Financial Results on Tuesday, May 13, 2025
-
Anavex Life Sciences (AVXL) Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
-
Anavex Life Sciences Announces Full Enrollment of Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
-
Anavex Life Sciences to Participate in The Citizens Life Sciences Conference
-
Anavex Life Sciences Announces Appointment of Dr. Audrey Gabelle, MD, PhD to the Scientific Advisory Board
-
Anavex Life Sciences Announces Presentation at 9th International Conference on Alzheimer’s Disease and Related Disorders in the Middle East
-
Anavex Life Sciences Announces Positive up to 4-Years Oral Blarcamesine Results from Phase IIb/III Open-Label Extension Trial in Early Alzheimer’s Disease
-
Anavex Life Sciences to Present at the 24th Annual Needham Virtual Healthcare Conference
-
Anavex Life Sciences to Present at the 45th Annual TD Cowen Health Care Conference
-
Anavex Life Sciences Reports Fiscal 2025 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2025 First Quarter Financial Results on Wednesday, February 12, 2025
-
Anavex Life Sciences (AVXL) Announces Issuance of Blarcamesine Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
-
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
-
Anavex Life Sciences Announces Issuance of Blarcamesine (ANAVEX®2-73) Composition of Matter U.S. Patent Expanding its Intellectual Property Portfolio
-
Anavex Life Sciences (AVXL) Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
-
Anavex Life Sciences Announces Peer-Reviewed Publication of Oral Blarcamesine Phase IIb/III Data in The Journal of Prevention of Alzheimer’s Disease
-
New Phase IIb/III Clinical Data Demonstrates Over Three Years of Continuous Treatment with Oral Blarcamesine to Significantly Benefit Early Alzheimer’s Disease Patients
-
Anavex Life Sciences to Present at the 43rd Annual J.P. Morgan Healthcare Conference
-
Anavex Life Sciences Reports Fiscal 2024 Fourth Quarter Financial Results and Provides Business Update
-
Blarcamesine Receives EMA Filing Acceptance for Treatment of Alzheimer’s Disease
-
Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
-
Anavex Life Sciences to Report New Long-Term Oral Blarcamesine Phase IIb/III Alzheimer’s Disease Data at J.P. Morgan 2025 Healthcare Conference
-
Anavex Life Sciences to Present at the 7th Annual Evercore ISI HealthCONx Conference 2024
-
Anavex Life Sciences Announces Submission of Blarcamesine MAA for Treatment of Alzheimer’s Disease to EMA
-
Anavex Life Sciences Announces Acceptance of Peer-Reviewed Manuscript of Oral Blarcamesine Phase IIb/III Data in a Reference Alzheimer’s Disease Journal
-
Anavex’s Blarcamesine Achieves Pre-specified Efficacy in Phase IIb/III Alzheimer’s Trial: Data Presented at CTAD Conference 2024
-
Anavex Life Sciences (AVXL) Reports Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX3-71
-
Anavex Life Sciences Announces Encouraging Preliminary Biomarker Results from Ongoing Phase 2 Study of ANAVEX®3-71 for the Treatment of Schizophrenia
-
Anavex Life Sciences to Present at the H.C. Wainwright 26th Annual Global Investment Conference 2024
-
Anavex Life Sciences Reports Fiscal 2024 Third Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 Third Quarter Financial Results on Tuesday, August 6, 2024
-
Anavex Life Sciences Announces Translational Biomarker Data for ANAVEX®2-73 (blarcamesine) in Fragile X Syndrome (Major Cause of Autism) at the 19th NFXF International Fragile X Conference
-
Anavex Life Sciences (AVXL): Results from Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Results from Anavex Life Sciences Landmark Phase IIb/III Trial of Blarcamesine Presented at Alzheimer's Association Conference
-
Anavex Life Sciences to Present at the H.C. Wainwright 5th Annual Neuro Perspectives Virtual Conference
-
Anavex Life Sciences (AVXL) announces addition and appointment of new senior team members
-
Anavex Life Sciences Announces Expansion of Leadership Team
-
Anavex Life Sciences to Present at the H.C. Wainwright 2nd BioConnect Investor Conference at NASDAQ
-
Anavex Life Sciences Reports Fiscal 2024 Second Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 Second Quarter Financial Results on Thursday, May 9th, 2024
-
Anavex Life Sciences to Present at the Noble Capital Markets Virtual Healthcare Equity Conference
-
Anavex Life Sciences to Present at the 23rd Annual Needham Virtual Healthcare Conference
-
Anavex Life Sciences Initiates Placebo-Controlled U.S. Phase 2 Clinical Trial of ANAVEX®3-71 in Schizophrenia
-
Anavex Life Sciences to Present at the 44th Annual TD Cowen Health Care Conference
-
Anavex Life Sciences Reports Fiscal 2024 First Quarter Financial Results and Provides Business Update
-
Anavex Life Sciences to Announce Fiscal 2024 First Quarter Financial Results on Wednesday, February 7th, 2024
-
Anavex Life Sciences (AVXL) Reports Publication Confirming Pharmacokinetic Dose Proportionality of ANAVEX3-71 in Humans
-
Anavex Life Sciences Reports Publication of ANAVEX®3-71 in Clinical Journal Confirming Pharmacokinetic Dose Proportionality of ANAVEX®3-71 in Humans
-
Anavex Life Sciences (AVXL) Announces Phase 2 Trial of ANAVEX3-71 in Schizophrenia
